NeOnc's $50mln cornerstone investment finalized, MENA expansion underway.
ByAinvest
Monday, Aug 11, 2025 9:05 am ET1min read
NEO--
The strategic partnership will enable NeOnc to establish a robust presence in the Middle East and North Africa (MENA) region, where advanced biotechnology infrastructure is currently lacking but offers significant market potential. The investment will also accelerate the development of NeOnc's clinical programs, NEO212 and NEO100, which are currently in Phase 2 trials.
Quazar Investment, a leading strategic investment firm headquartered in Abu Dhabi, will take majority control of NuroMENA Holdings following the investment closing. The arrangement will include joint governance oversight between NeOnc and Quazar to ensure strategic alignment and accelerate breakthrough CNS therapies across the region.
"This is a defining moment for NeOnc," said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. "With the finalization of NuroMENA’s incorporation and the support of Quazar Investment, we are now fully equipped to continue our goals toward delivering life-saving therapies to a region in urgent need of innovation."
Waleed K. Al Ali, Chairman and CEO of Quazar Investment, added, "We are proud to partner with NeOnc to bring cutting-edge biotechnology to the UAE and beyond. With NuroMENA now officially formed under ADGM, we are positioned to assist NeOnc with efforts to transform the landscape of brain cancer and CNS treatment across the region."
The official incorporation of NuroMENA Holdings Ltd. under ADGM on August 6, 2025, marks a critical milestone for NeOnc, fulfilling all contingencies for the $50 million strategic investment. This deal represents a significant capital infusion for a clinical-stage biotech company with multiple Phase 2 programs targeting the challenging CNS cancer space.
References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3130952/0/en/NeOnc-Technologies-Finalizes-All-Contingencies-for-50-Million-Strategic-Partnership-with-Quazar-Investment-as-NuroMENA-Holdings-Receives-ADGM-Incorporation.html
[2] https://www.marketscreener.com/news/neonc-technologies-finalizes-all-contingencies-for-50-million-strategic-partnership-with-quazar-inv-ce7c5ed2de81f424
[3] https://www.stocktitan.net/news/NTHI/ne-onc-technologies-finalizes-all-contingencies-for-50-million-xdu5lyturomj.html
NTHI--
NeOnc Technologies Holdings, a biotechnology company, has announced the official incorporation of NuroMENA Holdings Ltd by the Abu Dhabi Global Market. This milestone completes the $50 million cornerstone investment led by Quazar Investment, supporting the launch of NeOnc's CNS platform across the MENA region and accelerating its therapeutic pipeline development.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biotechnology company focused on therapies for central nervous system (CNS) cancers, has announced the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). This milestone completes the $50 million cornerstone investment led by Quazar Investment, supporting the launch of NeOnc's CNS platform across the MENA region and accelerating its therapeutic pipeline development.The strategic partnership will enable NeOnc to establish a robust presence in the Middle East and North Africa (MENA) region, where advanced biotechnology infrastructure is currently lacking but offers significant market potential. The investment will also accelerate the development of NeOnc's clinical programs, NEO212 and NEO100, which are currently in Phase 2 trials.
Quazar Investment, a leading strategic investment firm headquartered in Abu Dhabi, will take majority control of NuroMENA Holdings following the investment closing. The arrangement will include joint governance oversight between NeOnc and Quazar to ensure strategic alignment and accelerate breakthrough CNS therapies across the region.
"This is a defining moment for NeOnc," said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. "With the finalization of NuroMENA’s incorporation and the support of Quazar Investment, we are now fully equipped to continue our goals toward delivering life-saving therapies to a region in urgent need of innovation."
Waleed K. Al Ali, Chairman and CEO of Quazar Investment, added, "We are proud to partner with NeOnc to bring cutting-edge biotechnology to the UAE and beyond. With NuroMENA now officially formed under ADGM, we are positioned to assist NeOnc with efforts to transform the landscape of brain cancer and CNS treatment across the region."
The official incorporation of NuroMENA Holdings Ltd. under ADGM on August 6, 2025, marks a critical milestone for NeOnc, fulfilling all contingencies for the $50 million strategic investment. This deal represents a significant capital infusion for a clinical-stage biotech company with multiple Phase 2 programs targeting the challenging CNS cancer space.
References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3130952/0/en/NeOnc-Technologies-Finalizes-All-Contingencies-for-50-Million-Strategic-Partnership-with-Quazar-Investment-as-NuroMENA-Holdings-Receives-ADGM-Incorporation.html
[2] https://www.marketscreener.com/news/neonc-technologies-finalizes-all-contingencies-for-50-million-strategic-partnership-with-quazar-inv-ce7c5ed2de81f424
[3] https://www.stocktitan.net/news/NTHI/ne-onc-technologies-finalizes-all-contingencies-for-50-million-xdu5lyturomj.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet